LONDON (ShareCast) - (Sharecast News) - Alliance Pharma launched its prescription product for the treatment of nausea and vomiting of pregnancy across the UK on Tuesday.
Xonvea, Alliance's new licensed medicine aimed at women with NVP who have been failed by conservative management, is made up of a combination of doxylamine and pyridoxine and has been recommended as a first-line pharmacotherapy in the USA and Canada to more than 33m women.

Alliance's chief executive Peter Butterfield said the launch of Xonvea was "a significant milestone" for the firm.

"There is no other licensed treatment for nausea and vomiting of pregnancy in the UK so this is excellent news for patients and clinicians as it fulfils a significant unmet medical need," said Butterfield.

The Royal College of Obstetricians and Gynaecologists states that severe NVP is one of the most common reasons for pregnant women to be admitted to hospital.

As of 1025 BST, Alliance shares had shot up 7.69% to 72.80p.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE